8 Best Pet Stocks to Buy According to Billionaires
The pet industry is expected to continue growing in the coming years, driven by changing consumer preferences and innovative trends.
Zoetis Inc. (ZTS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Unisphere Establishment Hani Lazkani (Ceo) | 4,800,000 | $782,064,000 | 6.81% | |
| 2. | Cantillon Capital Management William Von Mueffling | 1,293,251 | $210,709,386 | +1% | 1.27% |
| 3. | Citadel Investment Group Ken Griffin | 1,090,499 | $177,675,002 | 0.03% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 788,429 | $128,458,739 | -3% | 0.15% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 676,635 | $110,244,141 | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.48 | 2,100 | Director | 7,590 | 2021-02-19 | Filing | |
| $164.89 | 2,900 | Director | 5,490 | 2021-02-19 | Filing | |
| $163.80 | 2,590 | Director | 2,590 | 2021-02-19 | Filing | |
| $74.56 | 10 | Director | 17 | 2018-01-11 | Filing | |
| $50.31 | 7 | Director | 7 | 2016-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $170.00 | 326 | Officer | 15,781 | 2025-03-10 | Filing | |
| $166.14 | 1,210 | Director | 11,245 | 2025-03-11 | Filing | |
| $156.68 | 382 | Officer, Director | 94,194 | 2025-02-19 | Filing | |
| $171.18 | 326 | Officer | 16,107 | 2025-02-11 | Filing | |
| $177.46 | 3,477 | Officer | 3,249 | 2024-11-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 139,675 | $22,997,489 | 0.33% | |
| 2. | 86,562 | $14,252,433 | 0.52% | |
| 3. | 38,804 | $6,389,079 | 0.18% | |
| 4. | 18,789 | $3,093,609 | 1.01% | |
| 5. | 3,095 | $509,592 | 0.09% |
News See All
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Zoetis (ZTS) Declined in Q4 Despite Posting Excellent Results
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S.
10 Best Weight Loss Drug Stocks to Buy According to Analysts
Most people have tried to include fitness and weight loss into their everyday routines.
What Makes Zoetis (ZTS) a Compelling Opportunity?
Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Zoetis Inc. (NYSE:ZTS) Q4 2024 Earnings Call Transcript
Operator: Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis.
10 Best Drug Stocks to Buy Now
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for medicines in China.
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. (ZTS) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.
Retirement Stock Portfolio: 10 Healthcare Stocks to Buy
Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential, and ability to provide steady income through dividends.
13 Best Pharma Dividend Stocks To Buy In 2024
The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, reflecting a shift toward smaller, more strategic transactions.
Billionaire Hedge Funds
